Product name: Mogroside IIa
Synonym name:
Catalogue No.: BP2038
Cas No.: 1613527-65-3
Formula: C42H72O14
Mol Weight: 801.024
Botanical Source: Siraitiae fructus
Physical Description:
Type of Compound: Triterpenoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
HPLC of Mogroside IIa
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Mogroside IIa is a natural triterpene sweet glycoside isolated from the traditional Chinese medicinal herb Siraitia grosvenorii, and is an important member of the monk fruit family. As a unique medicinal and edible plant unique to southern China, Luo Han Guo has long been used for seasoning and treating coughs, constipation, diabetes, and other diseases due to its natural sweetness and various bioactive components. In recent years, with in-depth research into the pharmacological functions of monk fruit glycoside compounds, monk fruit glycoside IIa has gradually become a hot topic in natural product pharmacology research due to its unique structure and significant biological activity, especially its potential in diabetes replacement therapy.
Luo Han Fruit Glycoside IIa not only has a sweetness regulation effect but also exhibits multiple pharmacological effects such as blood sugar regulation, antioxidant effects, and anti-inflammatory effects. Its mechanism of action involves multiple molecular targets, especially interactions with taste receptors and related signaling pathways, offering new ideas for the treatment of diabetes and metabolic syndrome. This paper will systematically review the chemical structure and physicochemical properties of monk fruit glycoside IIa, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics. Combined with current clinical application prospects, it will comprehensively assess its potential and development direction as an alternative drug for diabetes.
Luo Han Guoside IIa has the chemical formula C42H70O14 and a molecular weight of 801.0240, belonging to the triterpene class of sweet glycosides. Its structural core is a tetracyclic triterpene skeleton, connecting multiple β-D-glucosyl groups to form a highly polar glycoside structure. Monk fruit glycoside IIa and monk fruit glycoside I-A1 have similar structures and both contain multiple glucose residues, but there are subtle differences in the way and position of glycoside linking, affecting their bioactivity and pharmacokinetic properties.
In terms of physicochemical properties, the LogP value of monk fruit glycoside IIa is 2.5780, indicating moderate lipid solubility, which facilitates cell membrane penetration but is not easily accumulated in lipid environments. Its topological polar surface area (TPSA) is 239.2200, showing high polarity and reflecting the characteristics of its polysaccharide structure. Low water solubility (0.0599 mg/mL) suggests limited solubility in the aqueous phase, which may affect oral bioavailability. Low permeability of the blood-brain barrier indicates that monk fruit glycoside IIa has difficulty entering the central nervous system, reducing the risk of central side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenic test result was 0.0, indicating no significant genotoxicity.
In summary, the structural characteristics of monk fruit glycoside IIa give it good safety and moderate pharmacokinetic characteristics, but its relatively low water solubility and bioavailability remain challenges in future drug development.
Monk Fruit Glycoside IIa is mainly found in the fruit of monk fruit, especially in the flesh and cortex of mature fruit. As a member of the Cucurbitaceae family, monk fruit is rich in various sweet triterpene glycosides, including monk fruit glycoside I-A1, monk fruit glycoside IIa, and other homologs. The content of monk glycoside IIa is greatly influenced by factors such as fruit ripeness, planting environment, and harvest time.
Traditional extraction methods mainly rely on water extraction and alcohol extraction, combined with ultrasound-assisted extraction and enzymatic hydrolysis to improve extraction efficiency and purity. The specific process includes:
In recent years, green extraction technologies such as supercritical CO2 extraction and membrane separation have gradually been applied to the extraction of monk fruit glycoside IIa, balancing environmental friendliness and efficiency.
Research on the pharmacological activity of monk fruit glycoside IIa mainly focuses on its sweetness regulation, antidiabetic effects, antioxidant effects, and anti-inflammatory effects.
As a member of the monk fruit sweetness glycoside family, monk fruit glycoside IIa has remarkable sweetness, with sweetness about dozens of times that of sucrose. By activating the taste receptor T1R2/T1R3 complex, monk fruit glycoside IIa can mimic natural sweetness and is widely used as a sweetener alternative in sugar-free foods and beverages.
The need for treatment, especially for type 2 diabetes, has driven research into natural products. Monk fruit glycoside IIa affects insulin secretion and glucose metabolism by regulating taste receptor-related signaling pathways. In vitro and animal experiments have shown that monk fruit glycoside IIa can improve the function of pancreatic β cells, enhance insulin sensitivity, and lower blood sugar levels. In addition, it also provides certain protection against diabetic complications such as diabetic nephropathy and neuropathy.
Monk fruit glycoside IIa has the ability to scavenge free radicals, inhibit oxidative stress, and reduce inflammatory responses. By regulating signaling pathways such as NF-κB and MAPK, it reduces the expression of pro-inflammatory factors and protects cells from oxidative damage. These effects provide a theoretical basis for its adjunctive treatment in chronic metabolic diseases.
Some studies have also revealed the potential effects of monk fruit glycoside IIa in immune regulation, liver protection, and antitumor effects, suggesting its multi-target and multi-pathway pharmacological properties.
The main mechanism of action of monk fruit glycoside IIa involves the taste receptor complex and its downstream signaling pathways, with key targets in diabetes replacement therapy including:
Through these targets, monk fruit glycoside IIa not only regulates taste perception but also directly affects insulin secretion and glucose homeostasis. Additionally, monk fruit glycoside IIa protects pancreatic islet cells and target tissues by inhibiting oxidative stress and inflammatory signaling pathways, thereby reducing diabetes-related pathological damage.
The druggability evaluation of monk fruit glycoside IIa shows that it has certain development potential, but there are also challenges.
Due to its large molecular weight and complex glycoside structure, monk fruit glycoside IIa is absorbed slowly orally and has limited bioavailability. Its relatively high TPSA value and low water solubility limit intestinal absorption. Animal experiments show that monk glycoside IIa exhibits a relatively long half-life in plasma, mainly being metabolized by the gut microbiota into small molecule active metabolites to exert biological effects.
The hERG channel inhibition test was negative, and the Ames mutagenic test was negative, indicating that monk fruit glycoside IIa carries low risk of cardiotoxicity and genotoxicity. Long-term toxicological studies show it is well tolerated, with no significant organotoxicity observed.
Currently, there are no clear reports of significant interactions between monk fruit glycoside IIa and other drugs, but its potential to regulate metabolic enzymes and transporters requires further research.
The low water solubility and oral bioavailability of monk fruit glycoside IIa limit its clinical application. In the future, strategies such as nanocarriers, liposome encapsulation, and structural modification can be used to improve stability and absorption rates.
As a natural sweetener and candidate molecule for diabetes replacement therapy, Romonfruit Glycoside IIa has broad clinical application prospects.
Based on its mechanism of regulating taste receptors and insulin secretion, monk fruit glycoside IIa is expected to become an adjunct therapy for type 2 diabetes patients, improving blood sugar control and reducing the side effects of traditional drugs. Its natural sweetener properties are also suitable for diabetic patients to replace sucrose intake, reducing sugar load.
The antioxidant and anti-inflammatory effects of monk fruit glycoside IIa offer potential for adjunctive treatment in obesity, fatty liver, and cardiovascular diseases. Future clinical trials will need to further verify its efficacy and safety.
To promote the clinical translation of monk fruit glycoside IIa, the following aspects need to be strengthened:
Luo Han Guoside IIa is an important triterpene sweet glycoside in Luo Han Guo, combining natural sweetness with multiple pharmacological activities, and has shown unique advantages especially in the field of diabetes alternative therapy. By regulating taste receptors and related signaling pathways, it influences insulin secretion and glucose metabolism, supplemented by antioxidant and anti-inflammatory effects, providing new ideas for the comprehensive management of metabolic diseases. Although its low water solubility and bioavailability limit clinical application, with the development of extraction and purification technologies and drug delivery systems, the prospects for monk fruit glycoside IIa in drug development are broad. In the future, by combining systematic pharmacological mechanism research and clinical validation, it is expected that monk fruit glycoside IIa will be developed into a safe and effective natural metabolic regulator, benefiting a wide range of diabetes and metabolic disease patients.
